<scp>GIDEON</scp> (Global Investigation of therapeutic <scp>DE</scp> cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis - Concepedia

Concepedia

Publication | Open Access

<scp>GIDEON</scp> (Global Investigation of therapeutic <scp>DE</scp> cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

DOI Full Paper Access

222

Citations

17

References

2013

Year

Riccardo Lencioni, Masatoshi Kudo, Sheng‐Long Ye, J.‐P. Bronowicki, Xiaoping Chen, Lucy Dagher, Junji Furuse, J.F. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou,

International Journal of Clinical Practice

Abstract

Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.

References

	Year	Citations

Page 1